Introduction
Following the publication of the 4-S trial 1 and four subsequent trials of statins for the primary and secondary prevention of cardiovascular events 2-5 the benefits and importance of the reduction of lowdensity lipoprotein (LDL) cholesterol for patients with active vascular disease and those at high risk of developing such problems are now clearly established. 6 More recently in the VA-HIT trial 7 the use of gemfibrozil was associated with a 22% reduction in major cardiovascular events without any change in LDL-cholesterol. These trial data, along with those of the Helsinki Heart Study 8 suggest that modification of other lipid modalities-increasing serum high density lipoprotein (HDL) cholesterol levels and/or reducing serum triglyceride levelsmay have a major independent beneficial role in the management of dyslipidaemia for the prevention of cardiovascular disease.
Background and rationale
In an unpublished clinical audit (personal communication) of the effects of statins on lipid profiles of the three ethnic groups found in Singapore (Chinese, Indian, Malay) it has been noted that statins do not produce any change in HDL-cholesterol among the treated Indian population. If this observation were confirmed in a randomised trial setting it could have major implications for optimal lipidCorrespondence: Prof. NR Poulter, Cardiovascular Studies Unit, Department of Clinical Pharmacology, Imperial College School of Medicine, St Mary's Campus, London W2 1PG, UK. E-mail: n.poulterȰic.ac.uk lowering therapy for the South Asian community whose dyslipidaemia is characterised by low HDLcholesterol and raised triglycerides and who are particularly prone to coronary artery disease. The ASCOT trial in which approximately 2.6% and 4.5% of recruits from the UK are South Asian and African-Caribbean respectively, allows a comparison of the effects of statins on South Asian, whites and African-Caribbean (black) patients.
Objectives
(1) To compare the impact of atorvastatin (10 mg) on total cholesterol, HDL-cholesterol, and triglyceride levels in South Asian, white and AfricanCaribbean patients randomised to the lipid-lowering limb of the ASCOT trial in the UK. (2) To investigate the genetic basis for any significant ethnically-based differences in response to atorvastatin.
Methods

Recruitment details
All South Asian and African-Caribbean patients who have been randomised to the lipid-lowering limb of the ASCOT trial will be identified from the currently available database. For each of these recruits, three white patients also randomised into the lipid-lowering limb of the trial will be selected at random from the ASCOT database matched for age (±1 year), sex, study centre, and smoking status.
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Number of subjects
Approximately 146 South Asian and 286 'black' hypertensive patients have been randomised to the lipid-lowering limb of ASCOT. Data for these subjects and a further 1296 white recruits matched to these South Asian and black subjects will be analysed.
Analyses
Absolute and percentage changes in fasting lipid levels between baseline and the 6-month follow-up visit will be compared between South Asian, white, and African-Caribbean recruits. Paired t-tests will be used to compare South Asian with white recruits and African-Caribbean with white recruits. Adjustment in analyses will be made for baseline differences in potential confounding variables (eg, body mass index, alcohol intake) among groups by multiple linear regression.
The study will have 80% power at the 5% level to detect an absolute difference in the impact of atorvastatin on HDL-cholesterol between South Asian and white hypertensives of 4.5% (eg, 5% vs 0.5% increase in HDL). For the same comparisons among black hypertensives the study will have 96% power at the 5% level. The ASCOT Genetics Repository will contain 9000 participants from UK and Scandinavia. Recruitment should establish a powerful resource for testing relationships of genotypes of lipid genes and others to cholesterol level of baseline and after randomisation to atorvastatin vs placebo. In these specific studies, interest will be focussed on specific ethnic groups and the analysis will treat these groups separately. It is our intent, within the terms of the original informed consent study polymorphisms of lipid related genes in the hope of identification of genotypes, which predict treatment response. The numbers in each limb in specific ethnic groups will most likely be insufficient to make a meaningful relationship to endpoints, but may be sufficient to relate to size of lipid changes for a given dose of statin.
Inclusion and exclusion criteria
These criteria are those incorporated in the main study protocol. Ethnicity will be based on that reported in the ASCOT case record form, and/or where available the data collected in the ASCOT ethnicity study, and matched patients will be selected from the computerised database.
Ethical approval
Over and above those relating to the main ASCOT trial, there are no ethical implications associated with the execution of this sub-study.
Discussion
Based on clinical observational data from a lipid clinic in Singapore (personal communication) we hypothesize that HDL-cholesterol is not raised by statins in South Asian patients living in Singapore. A similar finding was not observed among the Chinese and Malay patients attending the same clinic in Singapore suggesting an ethnic difference in response to this class of lipid-lowering agent. To our knowledge no trial evidence has compared lipidlowering effects by statins across ethnic groups, to confirm or refute the observations made in Singapore. South Asians tend to have a dyslipidaemia characterised by low-HDL cholesterol and high triglycerides. 9 It might therefore have been expected that statins, which tend to produce a placebo-corrected increase in HDL-cholesterol of about 5%, [1] [2] [3] [4] [5] would produce a larger than usual rise in HDL in South Asian dyslipidaemic patients rather than no change as observed in the Singaporean clinic.
The numbers of South Asian hypertensive patients in the ASCOT trial who have been randomised to either atorvastatin (10 mg) or placebo is limited. However this database which already incorporates re-measurement of lipid levels 6 months after randomisation provides the opportunity with reasonable power (80%) to provide supportive evidence for this surprising but important finding.
Coronary heart disease (CHD) rates among the South Asian community in the UK and all other parts of the world to which they have migrated are significantly higher than most of the host populations. In the UK, for example, there is about a 45% excess of coronary heart disease among the South Asian community, a significant proportion of which has been attributed to the characteristic dyslipidaemia which forms part of their tendency towards insulin resistance. Based on trial evidence, one of, if not the most effective measure in both the primary and secondary prevention of CHD is lipid lowering with statins. It may be that fibrates are more effective than statins for CHD prevention in the context of any patient whose dyslipidaemia is characterised by low HDL-cholesterol and raised triglycerides and trials are in progress to evaluate this question. However if statins are less effective in South Asians than in whites on whom most trial evidence is based, fibrates rather than statins may be the preferred choice in the management of dyslipidaemia among South Asian patients. This substudy of the ASCOT trial will provide reasonably robust evidence of any ethnically-based differential effect of statins, at least in high risk South Asian hypertensive patients.
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